May 14, 2024

A Historic Turning Point: ODAC Unanimously Votes in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments

Minimal residual disease (MRD) testing has been recommended as an early endpoint in myeloma clinical trials by the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). If the recommendation is adopted by the FDA, it could lead to the accelerated approval of new treatments. 

Read more…